



5 July 2023

EXPIRY OF LISTED OPTIONS (ASX CODE: NOXOA)

Noxopharm Limited (ASX: NOX) wishes to advise that 21,303,249 quoted options, exercisable at \$0.30 (trading under ASX Code NOXOA) (**Options**) will expire at 5.00pm (**AEST**) on Monday, 14 August 2023 (**Expiry Date**).

Official quotation of the Options on ASX will cease at close of trading on Tuesday, 8 August 2023, being four business days before the Expiry Date.

The Company notes that the Options are substantially “out of the money”. Following discussions with the ASX, the Company will not be dispatching personalised notices to option holders in accordance with Item 5.3 of Appendix 6A to the Listing Rules.

In accordance with Item 5.2 of Appendix 6A, the Company provides the following information to holders of the Options:

- 1) the total number of Options on issue is 21,303,249;
- 2) the number of fully paid ordinary shares in the Company to be issued on the exercise and conversion of the Options is 21,303,249;
- 3) the exercise price for each Option is \$0.30 (30 cents);
- 4) the due date for payment of the exercise price (in cleared funds) is the Expiry Date;
- 5) if payment in cleared funds is not received by the Expiry Date, the Options will expire unexercised and all rights attaching to the Options will cease;
- 6) official quotation of the Options on ASX will cease at close of trading on Tuesday, 8 August 2023, being four business days before the Expiry Date;
- 7) the market price of the Company’s shares at the close of trading on Wednesday, 5 July 2023 was \$0.044, (4.4 cents) being the latest available market price of shares on ASX prior to this announcement;
- 8) during the three months preceding the date of this announcement:
 - the highest market price of the Company’s shares on ASX was \$0.115 (11.5 cents) on 5 April 2023; and
 - the lowest market price of the Company’s Shares on ASX was \$0.038 (3.8 cents) on 29 June 2023; and
- 9) as at the date of this announcement, there are no underwriting agreements in relation to the Options.

If the market price of the Company’s shares exceeds \$0.30 (30 cents) before the Expiry Date, the Company will immediately send an option expiry notice to holders of the Options.

You can access your personalised NOXOA listed option exercise form via your Automic shareholder portal by taking the following steps:

1. Visit <https://investor.automic.com.au/#/signup>
2. Enter your username and password and follow the prompts.
3. Once logged in, click on "Documents and Statements".
4. On the left click on "Other documents" and download the relevant or form.

To register for a shareholder portal:

5. Visit <https://investor.automic.com.au/#/signup>
6. Enter " NOXOPHARM LIMITED " in the Company Name Field ensuring that you select the Company name from the drop-down list
7. Enter your Holding Number as shown in your holding statement accessed above
8. Enter your postcode OR country of residence (only if outside Australia)
9. Tick the box "I'm not a robot" and then select "Next"
10. Complete the prompts to set up your username and password details

If you have any queries in relation to your holding or require assistance accessing your holding statement, please contact Automic on 1300 288 664 (within Australia) or +61 2 9698 5414 (international). Alternatively, you can also direct your enquiries to hello@automic.com.au.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

Its two innovative technology platforms – Chroma™ (oncology) and Sofra™ (inflammation and autoimmunity, including mRNA vaccine enhancement) – provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.



NOXOPHARM LIMITED | ACN 608 966 123

All Registry Communication to:



GPO Box 5193, Sydney NSW 2001
1300 288 664 (within Australia)
+61 2 9698 5414 (international)
hello@automic.com.au
www.automic.com.au

SRN/HIN: [HolderNumber]
Security Code: NOXOA
Option Expiry Date: 14 AUG 2023
Exercise Price: \$0.30
Options Held:[HoldingTotal]

NOTICE OF EXERCISE OF OPTIONS

I/we hereby exercise the following number of Options and make payment in Australian currency for the amount payable. Please allot me/us Ordinary Shares calculated on the basis of one Ordinary Share for every one Option which I/we exercise. I/We agree to accept such Ordinary Shares subject to the Constitution of Noxopharm Limited.

1. Number of Options to be Exercised
Total payment required. If the dollar amount paid results in a fraction of a share then the shares allotted will be rounded down. (multiply number of Options to be Exercised by \$0.30).
[] [] [] , [] [] [] , [] [] [] A\$ [] [] [] , [] [] [] , [] [] [] . [] []

2. Payment
Payment for the exercise of options can be made via Electronic Funds Transfer to the following bank account:
BSB: 083 004
Account Number: 96-666-4147
Account Name: Noxopharm Limited
When making your EFT payment please ensure that you use your registered holding name as your "payment description".
This completed exercise form should be returned to the our registry hello@automic.com.au or via mail
Automic
GPO Box 5193
Sydney NSW 2001

3. Contact details
Telephone Number ()
Contact Name (PLEASE PRINT)
Email Address
SUPPORT YOUR COMPANY: By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible).

4. Please sign below and return the form to the Company
Securityholder 1 Securityholder 2 Securityholder 3
Sole Director or Sole Director and Company Secretary Director Director / Company Secretary
NOTE: When signed under Power of Attorney, the attorney states that they have not received a notice of revocation. A certified copy of the Power of Attorney must be lodged with this exercise form.
Submitting your 'Notice of Exercise of Options':
Please return the completed and signed form together with your cheque payment (if payment by cheque) to the address provided.

[ReplaceNoImages]